Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents

Rational drug discovery and development requires biomarkers to inform on target modulation and treatment efficacy. Many aspects of metabolism are altered in cancer, compared to normal tissues, and are often regulated by oncogene activation. Non-invasive imaging of spatio-temporal effects of molecularly targeted anticancer agents on tumor metabolism has considerable potential in the development and use of personalized molecular medicine approaches to cancer treatment. Here we describe how non-invasive monitoring of metabolism, using primarily magnetic resonance spectroscopy (MRS), can be used to follow treatment with novel molecularly targeted anticancer agents. We discuss how the regulation of metabolic pathways by oncogenic signaling can affect MRS-detectable metabolic signals together with the physiological factors that can influence the measured changes. Finally, the translation of these metabolic measurements from pre-clinical models to patients will be discussed.

[1]  J. Griffiths,et al.  MRI & MRS assessment of the role of the tumour microenvironment in response to therapy , 2011, NMR in biomedicine.

[2]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[3]  R. Jain,et al.  Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. , 2011, Cancer research.

[4]  P. Workman,et al.  Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors , 2011, Current medicinal chemistry.

[5]  P. Workman,et al.  Resisting targeted therapy: fifty ways to leave your EGFR. , 2011, Cancer Cell.

[6]  T. Stricker,et al.  Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. , 2011, Seminars in oncology.

[7]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[8]  C. Dang,et al.  Therapeutic targeting of cancer cell metabolism , 2011, Journal of Molecular Medicine.

[9]  Hyunsuk Shim,et al.  Metabolic positron emission tomography imaging in cancer detection and therapy response. , 2011, Seminars in oncology.

[10]  John Kurhanewicz,et al.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. , 2011, Neoplasia.

[11]  Xiaoyuan Chen,et al.  Positron emission tomography imaging of cancer biology: current status and future prospects. , 2011, Seminars in oncology.

[12]  C. Nanni,et al.  Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET , 2010, Journal of experimental & clinical cancer research : CR.

[13]  J. Erickson,et al.  Glutaminase: A Hot Spot For Regulation Of Cancer Cell Metabolism? , 2010, Oncotarget.

[14]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[15]  S. Ronen,et al.  17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2 , 2010, Breast Cancer Research.

[16]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[17]  S. Shousha,et al.  Reproducibility of [11C]Choline-Positron Emission Tomography and Effect of Trastuzumab , 2010, Clinical Cancer Research.

[18]  M. Leach,et al.  Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition , 2010, Oncotarget.

[19]  C. Koch,et al.  Early detection of radiation therapy response in non‐Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging , 2010, NMR in biomedicine.

[20]  M. Leach,et al.  The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. , 2010, Cancer research.

[21]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[22]  E. Aboagye.  Phosphatidylcholine Metabolic Transformation and Progression Signature as a Pharmacodynamic Biomarker , 2010, Oncotarget.

[23]  W. Yung,et al.  Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. , 2010, Neuro-oncology.

[24]  Paul S Mischel,et al.  Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 , 2010, Journal of Translational Medicine.

[25]  M. Loda,et al.  Fatty acid synthase as a potential therapeutic target in cancer. , 2010, Future oncology.

[26]  E. Gottlieb,et al.  Targeting metabolic transformation for cancer therapy , 2010, Nature Reviews Cancer.

[27]  John Kurhanewicz,et al.  Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. , 2010, Cancer research.

[28]  J. Neal,et al.  Targeted therapies: Optimal first-line therapy for NSCLC with EGFR mutations , 2010, Nature Reviews Clinical Oncology.

[29]  M O Leach,et al.  Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy , 2009, British Journal of Cancer.

[30]  P. Hersey,et al.  Metabolic Approaches to Treatment of Melanoma , 2009, Clinical Cancer Research.

[31]  E. Aboagye,et al.  [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography. , 2009, Cancer research.

[32]  R. Foà,et al.  Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. , 2009, Neoplasia.

[33]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[34]  J. Klawitter,et al.  Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells , 2009, Clinical Cancer Research.

[35]  E. Aboagye,et al.  Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET , 2009, Journal of Nuclear Medicine.

[36]  A. Ortega,et al.  Glucose avidity of carcinomas. , 2009, Cancer letters.

[37]  T. Tsuruo,et al.  De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy , 2009, British Journal of Cancer.

[38]  M. Bergström,et al.  Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. , 2009, Nuclear medicine and biology.

[39]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[40]  S. Kaye,et al.  From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs , 2009, Clinical pharmacology and therapeutics.

[41]  P. Wipf,et al.  Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity , 2009, Molecular Cancer Therapeutics.

[42]  P. Waldenberger,et al.  The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT , 2009, Molecular Imaging and Biology.

[43]  Y. Ishikawa,et al.  ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. , 2008, Cancer research.

[44]  C. Schnell,et al.  Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.

[45]  Paul Workman,et al.  Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.

[46]  K. Kaluarachchi,et al.  Fatty acid synthase inhibition results in a magnetic resonance–detectable drop in phosphocholine , 2008, Molecular Cancer Therapeutics.

[47]  P. Kuo,et al.  FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial , 2008, Molecular Imaging and Biology.

[48]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[49]  P. Workman,et al.  Biomarkers In Early Clinical Trials: the Committed and the Skeptics , 2008, Clinical Cancer Research.

[50]  P. Atadja,et al.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. , 2008, Neoplasia.

[51]  Martin O Leach,et al.  Therapeutic target metabolism observed using hyperpolarized 15N choline. , 2008, Journal of the American Chemical Society.

[52]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[53]  F. Vesuna,et al.  Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. , 2008, Cancer research.

[54]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[55]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[56]  Jan Wolber,et al.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy , 2007, Nature Medicine.

[57]  Marcin Skrzypski,et al.  Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. , 2007, The Lancet. Oncology.

[58]  Ann D. King,et al.  In vivo proton magnetic resonance spectroscopy of breast lesions: an update , 2007, Breast Cancer Research and Treatment.

[59]  Ian Collins,et al.  New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.

[60]  P. Workman,et al.  Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. , 2006, Endocrine-related cancer.

[61]  M. Jacobs,et al.  Choline metabolism in cancer: implications for diagnosis and therapy , 2006, Expert review of molecular diagnostics.

[62]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[63]  M O Leach,et al.  Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. , 2006, The British journal of radiology.

[64]  N. Beckman,et al.  In Vivo MR Techniques in Drug Discovery and Development , 2006 .

[65]  D. Collins,et al.  MR for Clinical Pharmacological Studies in Cancer , 2006 .

[66]  T. Brown,et al.  In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi‐institutional trial , 2006, NMR in biomedicine.

[67]  Paul Workman,et al.  Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. , 2006, Journal of the National Cancer Institute.

[68]  P. Workman,et al.  Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis , 2006, Molecular Cancer Therapeutics.

[69]  Paul Workman,et al.  Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[70]  J. Griffiths,et al.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. , 2006, Cancer research.

[71]  V. Raman,et al.  RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. , 2005, Cancer research.

[72]  Julian Downward,et al.  PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP , 2005, Oncogene.

[73]  D. Samid,et al.  Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. , 2005, Biochimica et biophysica acta.

[74]  M. Leach,et al.  Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. , 2005, Cancer research.

[75]  S. Gottschalk,et al.  Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells , 2004, Clinical Cancer Research.

[76]  Lu Zhang,et al.  The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 , 2004, Cancer Research.

[77]  D. Megías,et al.  Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression , 2004, Cancer Research.

[78]  Z. Bhujwalla,et al.  Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer , 2004, Cancer Research.

[79]  J. Griffiths,et al.  Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. , 2003, Journal of the National Cancer Institute.

[80]  H. Degani,et al.  Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo (13)C MRS. , 2002, American journal of physiology. Endocrinology and metabolism.

[81]  P. Morin,et al.  Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. , 2002, Experimental cell research.

[82]  L. del Peso,et al.  Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. , 2002, International journal of oncology.

[83]  A. D. Van den Abbeele,et al.  Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.

[84]  R. Rosell,et al.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.

[85]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[86]  Jose M. Silva,et al.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy , 2002, Oncogene.

[87]  T. Hara,et al.  Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[88]  J. Lacal,et al.  Regulation of choline kinase activity by Ras proteins involves Ral–GDS and PI3K , 2002, Oncogene.

[89]  T. Powles,et al.  Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment , 1998, NMR in biomedicine.

[90]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[91]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.